Wave Life Sciences Q1 revenue jumps, beats analyst estimates

Wave Life Sciences

28/04/2026 12:38

Overview

U.S. biotech firm's Q1 revenue rose sharply, beating analyst expectations

Q1 net loss narrowed and beat analyst estimates

Company ended Q1 with $544.6 mln cash, expects runway into Q3 2028

Outlook

Wave expects to initiate Phase 2a INLIGHT trial for WVE-007 in 2Q 2026

Company expects regulatory feedback on accelerated approval pathway for WVE-006 mid-2026

Wave expects current cash and equivalents to fund operations into 3Q 2028

Result Drivers

PIPELINE PROGRESS - Co attributed Q1 performance to advances in clinical programs, including WVE-007 for obesity and WVE-006 for AATD

INCREASED REVENUE - Q1 revenue rose to $38.2 mln from $9.2 mln a year earlier, though co did not specify main sources of revenue growth

Company press release: ID:nGNX6bSbht

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 Revenue
Beat
$38.25 mln
$9.12 mln (13 Analysts)
Q1 EPS
-$0.13
Q1 Net Income
Beat
-$26.09 mln
-$61.11 mln (14 Analysts)
Q1 Income from Operations
Beat
-$31.30 mln
-$63.54 mln (15 Analysts)
Q1 Pretax Profit
Beat
-$26.09 mln
-$61.12 mln (13 Analysts)
Q1 Operating Expenses
$69.54 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 16 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for WAVE Life Sciences Ltd is $27.00, about 289% above its April 27 closing price of $6.94

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)